Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy

Blood Purification

Volumn 32, Issue 4, 2011, Pages 331-340

  Berto, Patrizia ^a   Ronco, Claudio ^b   Cruz, Dinna ^b   Melotti, Rita Maria ^c   Antonelli, Massimo ^d  

^a PBE Consulting   (Italy)

^b S Bortolo General Hospital Vicenza   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Apache score; Blood; Cost effectiveness analysis; Critical care; Economics; Endotoxins; Hemoperfusion; Hospital mortality; Intensive care units; Polymyxin; Polymyxin B; Septic shock

Indexed keywords

CATECHOLAMINE; NORADRENALIN; POLYMYXIN B;

ABDOMINAL DISEASE; ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EMERGENCY SURGERY; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; ITALY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPTIC SHOCK; SEX DIFFERENCE; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEMOPERFUSION; HUMANS; INTRAABDOMINAL INFECTIONS; ITALY; MALE; MIDDLE AGED; POLYMYXIN B; RETROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 80855133012     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000333826     Document Type: Article

References (29)

1. Cruz DN, Bellomo R, Ronco C: Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 444-451.
2. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et al: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004; 190: 527-534. (Pubitemid 38982092)
3. Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-114. (Pubitemid 36648053)
4. Rachoin JS, Foster D, Dellinger RP: Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 111-118.
5. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, et al: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11:R47.
6. Cruz DN, de Cal M, Piccinni P, Ronco C: Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 77-82.
7. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
8. Drummond M, Stoddard G, Torrance G: Methods for the Economic Evaluation of Healthcare Programmes. New York, Oxford University Press, 1987.
9. Gold MR, Siegel JE, Russel LB, Weinstein MC: Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996.
10. Gruppo di Lavoro AIES Coordinato da G. Fattore: Proposta di linee guida per la valutazione economica degli interventi sanitari: documento per la discussione. Pharmacoecon Ital Res Art 2009; 11: 83-93.
11. Di Loreto P: L'approccio della Regione dell'Umbria alla determinazione del tariffario per la remunerazione delle prestazioni di ricovero. Pharmacoecon Ital Res Art 2006; 8: 74-81. (Pubitemid 46211736)
12. Torbica A, Tarricone R, Calciolari V, Branca V, Gaini SM: Analisi dei costi del trattamento dell'aneurisma intracranico in Italia. Pharmacoecon Ital Res Art 2009; 11: 25-37.
13. Prontuario Farmaci del Sistema Sanitario Nazionale. http://www.giofil.it (accessed 20.7.2009).
14. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera. Decreto Ministeriale 13/12/2006.
15. ISTAT. Tavole di mortalità della popolazione italiana - Ripartizione: Italia - Femmine Anno: 2006. http://demo.istat.it (accessed 20.7.2009).
16. ISTAT. Tavole di mortalità della popolazione italiana - Ripartizione: Italia - Maschi Anno: 2006. http://demo.istat.it (accessed 20.7.2009).
17. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: Apache - acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981; 9: 591-597.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Apache II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829. (Pubitemid 15250137)
19. Briggs AH, Wonderling DE, Mooney CZ: Pulling CEA up by its bootstraps: a nonparametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340. (Pubitemid 27384638)
20. Desgagne A, Castilloux AM, Angers JF, Le- Lorier J: The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998; 13: 487-497.
21. Hunink MG, Bult JR, de Vries J, Weinstein MC: Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18: 337-346. (Pubitemid 28307565)
22. Antonelli M, Fumagalli R, Cruz DN, Brienza N, Giunta F: PMX endotoxin removal in the clinical practice: results from the EUPHAS trial. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 83-90.
23. Appleby J: Data briefing. The NICE threshold. Health Serv J 2007; 117: 21.
24. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K: Searching for cost-effectiveness thresholds in the NHS. Health Policy 2009; 91: 239-245.
25. Messori A, Santarlasci B, Trippoli S, Vaiani M: Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metodologia di applicazione di un algoritmo farmacoeconomico. Pharmacoecon Ital Res Art 2003; 5: 53-67. (Pubitemid 37220615)
26. Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, Puntorieri V, Martin EL, Mascia L, Monti G, et al: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008; 34: 1638-1645.
27. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De BD, Brett S, Marzo D, et al: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-405. (Pubitemid 40571661)
28. Clin Tri Id.NCT01046669: Safety and efficacy of polymyxin B hemoperfusion (PMX) for septic shock (EUPHRATES). http//www.clinicaltrials.gov (accessed 20.7.2009).
29. EUPHAS2: a web-based prospective multicentered, collaborative data collection project. http://www.euphas2.eu/en (accessed 20.7.2009).